证券代码：688029 证券简称：南微医学 公告编号：2025-027 南微医学科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 是否涉及差异化分红送转：是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经南微医学科技股份有限公司（以下简称"公司"）2025 年 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东 （公司回购专用证券账户除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章 及其他规范性文件以及《公司章程》的有关规定，公司回购专用证券账户中的股 份不享有股东大会表决权、利润分配、公积金转增股本、认购新股等权利。 （1）差异化分红方案 根据公司 2024 年年度股东大会审议通过的《关于 <公司 ensp="ensp" 年年度利润分配="年年度利润 分配"> ? 每 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Nanwei Medical, which has a current stock price of 65.72 yuan and a market capitalization of 12.345 billion yuan, with a rolling PE ratio of 21.63 times [1] - The medical device industry has an average PE ratio of 49.56 times and a median of 36.18 times, placing Nanwei Medical at the 49th position in the industry ranking [1][2] - As of the first quarter of 2025, 17 institutions hold shares in Nanwei Medical, including 11 funds, with a total shareholding of 106.4733 million shares valued at 7.017 billion yuan [1] Group 2 - Nanwei Medical specializes in the research, development, manufacturing, and sales of minimally invasive medical devices, with key products including biopsy, hemostasis, EMR/ESD, dilation, ERCP, EUS/EBUS devices, ablation instruments, disposable imaging systems, and related consumables [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 699 million yuan, a year-on-year increase of 12.75%, and a net profit of 161 million yuan, also reflecting a year-on-year increase of 12.18%, with a gross profit margin of 65.69% [1]

| 回购方案首次披露日 | 2025/4/22，由董事长隆晓辉先生提议 | | --- | --- | | 回购方案实施期限 | 2025/4/22~2025/10/21 | | 预计回购金额 | 3,000万元~5,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 15,729股 | | 累计已回购股数占总股本比例 | 0.0084% | | 累计已回购金额 | 977,391.73元 | | 实际回购价格区间 | 62.01元/股~62.32元/股 | 一、回购股份的基本情况 证券代码：688029 证券简称：南微医学 公告编号：2025-026 南微医学科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 特此公告。 南微医学科技股份有限公司董事会 2025 年 6 月 4 日 2025 年 4 月 21 日，南微医学科技股份有限公司（以 ...

Core Viewpoint - The company, Nanwei Medical Technology Co., Ltd., is currently involved in a patent invalidation request initiated by Beijing Zhongke Shengkang Technology Co., Ltd., which may impact its patent rights and potential compensation from a previous infringement lawsuit [1][2]. Group 1: Case Background - The case is at the stage of acceptance and has not yet been reviewed [1]. - The company is the patent holder involved in the dispute [1]. - The patent in question is for a hemostatic clip (Patent No. 201410222753.7), which was applied for on May 23, 2014, and granted on November 18, 2015 [2]. Group 2: Previous Litigation - The company initiated a patent infringement lawsuit against Zhongke Shengkang, which resulted in a ruling that found Zhongke Shengkang guilty of infringement, ordering them to cease infringing activities and pay the company 700,000 yuan [2]. - Zhongke Shengkang has appealed the first-instance judgment to the Supreme People's Court, and the case is still under review [2]. Group 3: Impact on Company - If the patent is ultimately declared invalid, competitors may use the technology without compensation to the company, affecting the potential recovery from the previous lawsuit [1][3]. - The company asserts that the invalidation of the patent will not significantly impact its production and sales, as it has a robust core technology system that includes multiple patents and technical know-how [4]. - The company reported that its domestic sales of products utilizing the disputed patent were approximately 100 million yuan in 2024 [3].

证券代码：688029 证券简称：南微医学 公告编号：2025-025 南微医学科技股份有限公司 关于收到《无效宣告请求受理通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 南微医学科技股份有限公司（以下简称"公司"）于2022年9月向北京中科盛 康科技有限公司（以下简称"中科盛康"，即本事项无效宣告请求人）发起专利侵 权诉讼，经北京知识产权法院一审判决认定中科盛康构成侵权，判令其停止侵权行 为并赔偿公司70万元。中科盛康不服一审判决，上诉至最高人民法院。截至本公告 披露日，案件尚在审理中。2025年5月16日，中科盛康向国家知识产权局对公司相 关发明专利提出无效宣告请求。2025年5月28日，国家知识产权局经形式审查符合 有关规定，准予受理。对于本次事项，如涉案专利被最终认定无效，公司竞争对手 可以无偿、合法地使用其所涉及的技术方案，公司对中科盛康发起的专利诉讼将无 法获得赔偿。但专利无效不影响公司继续生产、销售使用该专利的公司产品，不会 对公司生产经营构成重大不利影响。鉴于本次事项尚无最终 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Nanwei Medical, indicating a decline in stock price and a relatively low PE ratio compared to the industry average [1][2] - As of May 26, Nanwei Medical's closing stock price was 65.37 yuan, down 1.60%, with a rolling PE ratio of 21.52 times and a total market capitalization of 12.28 billion yuan [1] - The average PE ratio for the medical device industry is 48.92 times, with a median of 35.68 times, placing Nanwei Medical at the 49th position in the industry ranking [1][2] Group 2 - As of March 31, 2025, Nanwei Medical had 13,313 shareholders, an increase of 639 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's main business involves the research, development, manufacturing, and sales of minimally invasive medical devices, including biopsy, hemostasis, closure, EMR/ESD, dilation, ERCP, EUS/EBUS products, ablation devices, disposable biliary imaging systems, and bronchoscopes [1] - In the first quarter of 2025, Nanwei Medical reported a revenue of 699 million yuan, a year-on-year increase of 12.75%, and a net profit of 161 million yuan, also reflecting a year-on-year increase of 12.18%, with a gross profit margin of 65.69% [1]

Meeting Details - The shareholders' meeting of Nanwei Medical Technology Co., Ltd. was held on May 20, 2025, at the company's conference room in Nanjing [1] - A total of 135 ordinary shareholders attended the meeting, holding 113,576,530 voting rights, which accounts for 60.76% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved with significant majority support, including: - Proposal 1: 99.9742% approval from ordinary shareholders [1] - Proposal 2: 99.9732% approval from ordinary shareholders [1] - Proposal 3: 99.9670% approval from ordinary shareholders [1] - Proposal 4: 99.3865% approval from ordinary shareholders [1] - The voting methods used were a combination of on-site and online voting, which complied with the Company Law and the company's articles of association [1] Legal Compliance - The meeting's procedures and voting results were confirmed to be legal and valid by the attending lawyers, ensuring compliance with relevant laws and regulations [2][3]

江苏新高的律师事务所 关于 2024 年年度股东大会的见证法律意见书 见证法律意见书 地址：南京市秦淮区龙蟠中路 419 号人保（南京）金融大厦 A 座 9、10 楼 电话：（025）84715285 传真：（025）84703306 邮编：210001 江苏新高的律师事务所 关于南微医学科技股份有限公司 2024 年年度股东大会的见证法律意见书 南微医学科技股份有限公司 2024 年年度股东大会的 江苏新高的律师事务所 关于南微医学科技股份有限公司 苏高律股字[2025]第[0502]号 致：南微医学科技股份有限公司 江苏新高的律师事务所（以下简称"本所"）接受南微医学科技股份有限公 司（以下简称"公司"）委托，指派陆佳佩、张玫律师（以下简称"本所律师"） 出席公司 2024 年年度股东大会（以下简称"本次股东大会"），就本次股东大 会的合法性进行见证并出具法律意见书。 本法律意见书依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规 则》（以下简称"《规则》"）等相关法律、法规和规范性文件以及《南微医学 科技股份有限公司章程》（以 ...

证券代码：688029 证券简称：南微医学 公告编号：2025-024 南微医学科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 20 日 （二） 股东大会召开的地点：南京江北新区药谷大道 199 号公司 9 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 135 | | --- | --- | | 普通股股东人数 | 135 | | 2、出席会议的股东所持有的表决权数量 | 113,576,530 | | 普通股股东所持有表决权数量 | 113,576,530 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 60.7603 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 60.7603 | （四） ...

Core Viewpoint - The annual general meeting of Nanwei Medical Technology Co., Ltd. is set to discuss various proposals, including the confirmation of director and supervisor remuneration for 2024 and 2025, as well as the financial reports and budget for 2025 [1][2][3]. Meeting Procedures - The meeting will ensure the verification of attendees' identities and maintain order to protect shareholders' rights [2][3]. - Attendees must register before the meeting starts, and the meeting will follow a predetermined agenda for discussion and voting on proposals [2][3][4]. - Shareholders have the right to speak, inquire, and vote during the meeting, with specific rules governing the conduct of discussions and questions [2][3][4]. Proposals Overview - Proposal 1: Review of the 2024 Board of Directors' Work Report, which summarizes the previous year's activities and outlines priorities for 2025 [6]. - Proposal 2: Review of the 2024 Supervisory Board's Work Report, detailing the past year's work and future focus [8]. - Proposal 3: Review of the 2024 Financial Settlement Report, which includes a provision for credit and asset impairment totaling approximately 62.41 million yuan [8][9]. - Proposal 4: Review of the 2025 Financial Budget Report, projecting revenue of approximately 3.258 billion yuan, representing an 18% increase [10]. - Proposal 5: Review of the 2024 Annual Report and Summary, which has been approved by the Board [10][11]. - Proposal 6: Review of the 2024 Profit Distribution Plan, proposing a cash dividend distribution based on the total share capital [11][12]. - Proposal 7: Confirmation of the remuneration plan for directors and supervisors for 2024 and 2025, detailing specific amounts for independent directors and performance bonuses for the chairman [13][15]. Financial and Operational Highlights - The company plans to apply for a comprehensive credit limit of up to 1.2 billion yuan from commercial banks to support daily operations and reduce financing costs [16]. - The company has reported a total distributable profit of approximately 1.54 billion yuan as of December 31, 2024, with a proposed cash dividend distribution of 186.94 million yuan [12][13]. Independent Director's Report - The independent director's report emphasizes adherence to legal regulations and the importance of maintaining independence while fulfilling responsibilities [18][32]. - The independent director has actively participated in board meetings and committees, ensuring compliance and effective decision-making [21][35].